2,852
edits
Psychedelic Therapy Inclusion and Exclusion Criteria: Difference between revisions
Psychedelic Therapy Inclusion and Exclusion Criteria (view source)
Revision as of 06:30, 17 July 2023
, 06:30, 17 July 2023→Exclusion Criteria
mNo edit summary |
|||
| Line 27: | Line 27: | ||
2. Prior electroconvulsive therapy and/or ketamine for current episode. | 2. Prior electroconvulsive therapy and/or ketamine for current episode. | ||
3. Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI at Screening and Baseline. | 3. Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI at Screening and Baseline with the exception of those taking MAOI containing psychedelics including but not exclusively ayahuasca. | ||
4. Current psychological therapies that would not remain stable within 21 days the psychedelic administration session. Psychological therapies cannot be initiated within 21 days of Baseline. | 4. Current psychological therapies that would not remain stable within 21 days the psychedelic administration session. Psychological therapies cannot be initiated within 21 days of Baseline. | ||